

4-, 6- 或 7- 位取代苯基亚胺次甲基香豆素的合成及其抗癌活性

徐 嵩, 徐世平*, 李兰敏

(中国医学科学院、中国协和医科大学药物研究所, 北京 100050)

摘要: 目的 设计合成一系列香豆素西佛碱化合物并进行抗癌筛选。方法 合成了 21 个取代的 4-, 6- 或 7- 位苯基亚胺次甲基香豆素, 其结构经 MS, HNMR 和元素分析确证, 并对其进行体外抗癌筛选。结果 12 个化合物(3c, 3d, 3e, 3f, 3g, 3h, 3j, 3k, 3m, 3o, 3p, 3q) 分别对 KB, HCT-8, Be17402 细胞株有效。结论 该类化合物有一定抗癌活性, 值得进一步研究。

关键词: 香豆素; 西佛碱; 抗癌活性

中图分类号: R916.4; R962.1

文献标识码: A

文章编号: 0513-4870(2002)02-0113-04

香豆素类化合物有抑制癌细胞、增强免疫、诱导细胞凋亡等生理活性^[1]。前文^[2,3]报道取代的 4-, 6- 或 7- 位苯基亚胺次甲基香豆素(A 类)具有一定的抑癌活性, 在此基础上, 本文根据药物设计的电子等排原

理, 以 N 原子代替 =CH 原子团, 将乙烯基 CH=CH 换成其电子等排体 CH=N, 设计合成了取代的 4-, 6- 或 7- 位苯基亚胺次甲基香豆素(西佛碱, B 类, 图 1), 并考察了 B 类的抑癌活性。




Figure 1 Structures of compounds series A and B

4-甲酰基香豆素^[4]由不同取代的 4-甲基香豆素用二氧化硒氧化制备, 由于 2-位羰基拉电子作用使 4-位甲基被选择性氧化, 苯环上的甲基不被氧化。6-或 7-甲酰基香豆素由另一条路线, 用 NBS 溴化香豆素 6-或 7-位甲基后, 经六次甲基四胺氧化制得^[5,6], 4-位甲基不被溴化-氧化。

西佛碱的合成系采用 4-, 6- 或 7- 甲酰基香豆素和不同取代的苯胺, 以冰醋酸催化, 在乙醇中回流的条件下进行。生成的西佛碱在乙醇中的溶解度较原料小, 从溶液中析出。但是, 由于该反应是可逆的, 产物在质子性溶剂中加热会分解为原料, 所以

只能用非质子性溶剂丙酮重结晶。合成路线见 Scheme 1。

该反应的收率和产物的稳定性由醛基和氨基的反应活性决定: (1) 苯胺的邻、对位有推电子取代基如羟基时, 通过共轭效应使氨基亲核性增强, 收率高, 产物在溶液中较稳定; 苯环上有吸电子取代基如羧基时, 收率低, 产物在溶剂中不稳定, 易分解为原料。(2) 4-甲酰基香豆素反应活性稍高, 在本文实验条件下可以和对氨基苯甲酸及其乙酯反应; 但与间氨基苯酚、邻或间氨基苯甲酸反应只能得到产物与原料的混合物, 且难以纯化; 不与对氨基苯磺酸反应。(3) 6-或 7-甲酰基香豆素反应活性较低, 只与邻或对氨基苯酚反应; 与间氨基苯酚、邻、间或对氨基苯甲酸反应只能得到产物与原料的混合物。

我们合成了 21 个新化合物, 理化数据和元素分

收稿日期: 2001-06-07.

作者简介: 徐世平(1935-), 男, 研究员, 硕士生导师.

* 通讯作者 Tel: (010) 63165247, Fax: (010) 63017757,


E-mail: xusp@imm.ac.cn

析见表 1, 经核磁共振氢谱、质谱确证其结构(表 2)。

核磁氢谱显示该类化合物碳氮双键上的氢出现在低场, 6-位取代物的 CH=N 氢化学位移在 δ 8.65 ~ 8.70, 7-位 6-位取代物的 CH=N 氢化学位移在 δ 8.67 ~ 8.76, 4-位 CH=N 氢化学位移在 δ 8.81 ~ 9.03。质谱均显示分子离子峰, 且多为基峰, 表明这些化合物


还是相当稳定的。

所合成的 21 个化合物进行了体外抑制癌细胞活性筛选, 所用瘤株为人早幼粒白血病细胞 HL-60, 人口腔上皮癌细胞 KB, 人结肠癌细胞 HCT-8, 人肝癌细胞 Bel-7402。其中 12 个化合物对 KB, HCT-8 和 Bel-7402 细胞有效(表 3)。



Scheme 1 Route of synthesis of compounds 1, 2 and 3

Table 1 Physical constants and elemental analysis of compounds 1a ~ b, 2a ~ b and 3a ~ q



Compd.	Formula	R'	R'	Yield/ %	MP/ °C	Elemental analysis					
						Calculated			Measured		
						C	H	N	C	H	N
1a	C ₁₆ H ₁₁ NO ₃		4'-OH	74.6	237	72.44	4.18	5.28	72.94	4.20	5.46
1b	C ₁₆ H ₁₁ NO ₃		2'-OH	75.4	147	72.44	4.18	5.28	71.91	4.21	5.26
2a	C ₁₇ H ₁₃ NO ₃		4'-OH	62.8	224	73.11	4.69	5.02	73.00	4.74	5.25
2b	C ₁₇ H ₁₃ NO ₃		2'-OH	67.6	197	73.11	4.69	5.02	73.02	4.75	5.18
3a	C ₁₇ H ₁₃ NO ₃	7-CH ₃	4'-OH	98.7	211	73.11	4.69	5.02	72.85	4.51	4.92
3b	C ₁₇ H ₁₃ NO ₃ · H ₂ O	7-CH ₃	2'-OH	70.9	164	68.68	5.09	4.71	68.57	4.57	4.75
3c	C ₁₈ H ₁₅ NO ₃ · H ₂ O	6-CH ₃ , 7-CH ₃	4'-OH	83.6	214	69.44	5.51	4.50	69.52	5.41	4.88
3d	C ₁₈ H ₁₅ NO ₃	6-CH ₃ , 7-CH ₃	2'-OH	76.8	215	73.70	5.16	4.78	73.62	5.34	4.97
3e	C ₁₇ H ₁₃ NO ₄ · 1/2 H ₂ O	7-OCH ₃	4'-OH	86.5	190	67.10	4.64	4.60	67.05	4.53	4.38
3f	C ₁₇ H ₁₃ NO ₄ · 2/3 H ₂ O	7-OCH ₃	2'-OH	62.3	169	66.44	4.70	4.60	67.05	4.53	4.38
3g	C ₁₈ H ₁₅ NO ₄	7-OCH ₃	4'-OCH ₃	87.4	167	69.89	4.89	4.53	70.00	4.94	4.63
3h	C ₁₈ H ₁₃ NO ₅	7-OCH ₃	4'-COOH	41.0	290	66.87	4.05	4.33	66.75	4.22	4.30
3i	C ₂₀ H ₁₇ NO ₅	7-OCH ₃	4'-COOEt	78.5	188	68.37	4.88	3.99	68.33	4.79	4.29
3j	C ₁₈ H ₁₅ NO ₅	7,8-OCH ₃	4'-OH	82.1	214	66.45	4.65	4.31	66.66	4.72	4.18
3k	C ₁₈ H ₁₅ NO ₅	7,8-OCH ₃	2'-OH	72.5	192	66.45	4.65	4.31	66.23	4.51	4.20
3l	C ₂₃ H ₂₅ NO ₄ · 1/3 H ₂ O	6-rr Hex, 7-OCH ₃	4'-OH	64.9	172	71.67	6.71	3.63	71.74	6.85	3.52
3m	C ₂₃ H ₂₅ NO ₄	6-rr Hex, 7-OCH ₃	2'-OH	76.8	215	73.62	5.34	4.97	73.70	5.16	4.78
3n	C ₁₈ H ₁₅ NO ₄	7-OCH ₃ , 8-CH ₃	4'-OH	82.1	218	69.89	4.89	4.53	69.73	4.91	4.52
3o	C ₁₈ H ₁₅ NO ₄	7-OCH ₃ , 8-CH ₃	2'-OH	91.5	233	69.89	4.89	4.53	69.66	4.88	4.82
3p	C ₁₈ H ₁₃ NO ₅ · H ₂ O	7-OAc	4'-OH	57.6	182	63.34	4.43	4.10	63.44	4.11	3.97
3q	C ₁₈ H ₁₃ NO ₅	7-OAc	2'-OH	59.4	152	66.87	4.05	4.33	67.06	4.26	4.44

* If not noted, R or R' = all H

Table 2 Data of ¹H NMR Spectroscopy and EI-MS of compounds 1a ~ b, 2a ~ b and 3a ~ q

Compd.	¹ H NMR(DMSO d ₆)	EI-MS
1a	6.45(d, 1H, J=9 Hz, 3-H), 6.69(d, 2H, J=8 Hz, 3', 5'-H), 7.14(d, 2H, J=8 Hz, 2', 6'-H), 7.40(d, 1H, J=8 Hz, 8-H), 8.03(dd, 1H, J=8/2 Hz, 7-H), 8.06(d, 1H, J=9 Hz, 4-H), 8.12(d, 1H, J=2 Hz, 5-H), 8.65(s, 1H, CH=N), 9.37(s, 1H, OH)	265(100%, M ⁺), 264, 236, 120
1b	6.50(d, 1H, J=9 Hz, 3-H), 6.79~7.23(m, 4H, Ar'-H), 7.45(d, 1H, J=8 Hz, 8-H), 8.07(d, 1H, J=9 Hz, 4-H), 8.13(dd, 1H, J=8/2 Hz, 7-H), 8.28(d, 1H, J=2 Hz, 5-H), 8.70(s, 1H, CH=N)	265(100%, M ⁺), 264, 236, 120
2a	2.45(s, 3H, 4-CH ₃), 6.20(s, 1H, 3-H), 6.75(d, 2H, J=8 Hz, 3', 5'-H), 7.23(d, 2H, J=8 Hz, 2', 6'-H), 7.75~7.83(m, 3H, 5, 6, 8-H), 8.67(s, 1H, CH=N), 9.51(s, 1H, OH)	265(M ⁺), 262, 250, 234, 174, 120(100%)
2b	2.44(s, 3H, 4-CH ₃), 6.38(s, 1H, 3-H), 6.79~7.23(m, 4H, Ar'-H), 7.75~8.00(m, 3H, 5, 6, 8-H), 8.76(s, 1H, CH=N), 8.99(s, 1H, OH)	279(M ⁺), 262, 250, 234, 174, 120(100%)
3a	2.41(s, 3H, 7-CH ₃), 6.78(s, 1H, 3-H), 6.79(d, 2H, J=8 Hz, 3', 5'-H), 7.10(d, 1H, J=2 Hz, 8-H), 7.15(dd, 1H, J=8/2 Hz, 6-H), 7.34(d, 2H, J=8 Hz, 2', 6'-H), 8.68(d, 1H, J=8 Hz, 5-H), 8.83(s, 1H, CH=N), 9.67(s, 1H, OH)	279(100%, M ⁺), 262, 250, 236, 224, 187, 132, 120
3b	2.44(s, 3H, 7-CH ₃), 6.72~7.41(m, 7H, 3, 6, 8, Ar'-H), 8.60(d, 1H, J=8 Hz, 5-H), 8.96(s, 1H, CH=N), 9.67(s, 1H, OH)	279(100%, M ⁺), 262, 250, 234, 120
3c	2.31(s, 6H, 6, 7-CH ₃), 6.77(s, 1H, 3-H), 6.82(d, 2H, J=8 Hz, 3', 5'-H), 7.19(s, 1H, 8-H), 7.37(d, 2H, J=8 Hz, 2', 6'-H), 8.50(s, 1H, 5-H), 8.87(s, 1H, CH=N), 9.72(s, 1H, OH)	293(100%, M ⁺), 278, 276, 265, 264, 250, 237, 188, 146, 120
3d	2.31, 2.34(each s, 6H, 6, 7-CH ₃), 6.87~7.44(m, 6H, 3, 8, Ar'-H), 8.46(s, 1H, 5-H), 9.03(s, 1H, CH=N), 9.39(s, 1H, OH)	293(100%, M ⁺), 278, 276, 265, 264, 248, 186, 120
3e	3.87(s, 3H, 7-OCH ₃), 6.72(d, 1H, J=2 Hz, 8-H), 6.83(d, 2H, J=8 Hz, 3', 5'-H), 7.02(s, 1H, 3-H), 6.99(dd, 1H, J=8/2 Hz, 6-H), 7.38(d, 2H, J=8 Hz, 2', 6'-H), 8.80(d, 1H, J=8 Hz, 5-H), 8.85(s, 1H, CH=N), 9.75(s, 1H, OH)	295(100%, M ⁺), 278, 267, 266, 252, 148, 120
3f	3.87(s, 3H, 7-OCH ₃), 6.86~7.37(m, 7H, 3, 6, 8, Ar'-H), 8.71(d, 1H, J=8 Hz, 5-H), 8.85(s, 1H, CH=N), 9.36(s, 1H, OH)	295(100%, M ⁺), 278, 267, 266, 250, 148, 120
3g	3.81, 3.87(each s, 6H, 7, 4'-OCH ₃), 6.73(d, 1H, J=2 Hz, 8-H), 6.99(d, 3H, J=8 Hz, 6, 3', 5'-H), 7.00(s, 1H, 3-H), 7.44(d, 2H, J=8 Hz, 2', 6'-H), 8.77(d, 1H, J=8 Hz, 5-H), 8.84(s, 1H, CH=N)	309(100%, M ⁺), 294, 292, 281, 266, 250, 238, 148, 120
3h	3.86(s, 3H, 7-OCH ₃), 6.81(d, 1H, J=2 Hz, 8-H), 6.97(dd, 1H, J=8/2 Hz, 6-H), 7.02(s, 1H, 3-H), 7.41(d, 2H, J=8 Hz, 3', 5'-H), 8.00(d, 2H, J=8 Hz, 2', 6'-H), 8.72(d, 1H, J=8 Hz, 5-H), 8.83(s, 1H, CH=N), 12.30(s, 1H, COOH)	323(100%, M ⁺), 306, 295, 294, 267, 250, 190, 148, 120
3i	1.35(t, 3H, J=7 Hz, Et-CH ₃), 3.87(s, 3H, 7-OCH ₃), 4.25(q, 2H, J=7 Hz, Et-CH ₂ -), 6.85(d, 1H, J=2 Hz, 8-H), 7.00(dd, 1H, J=8/2 Hz, 6-H), 7.06(s, 1H, 3-H), 7.47(d, 2H, J=8 Hz, 3', 5'-H), 8.04(d, 2H, J=8 Hz, 2', 6'-H), 8.76(d, 1H, J=8 Hz, 5-H), 8.87(s, 1H, CH=N)	351(100%, M ⁺), 334, 323, 306, 295, 278, 250, 234, 148(100%), 120
3j	3.80, 3.90(each s, 6H, 7, 8-OCH ₃), 6.70(s, 1H, 3-H), 6.81(d, 2H, J=8 Hz, 3', 5'-H), 7.08(d, 1H, J=8 Hz, 6-H), 7.34(d, 2H, J=8 Hz, 2', 6'-H), 8.54(d, 1H, J=8 Hz, 5-H), 8.81(s, 1H, CH=N), 9.72(s, 1H, OH)	325(100%, M ⁺), 310, 297, 282, 254, 120
3k	3.84, 3.94(each s, 6H, 7, 8-OCH ₃), 6.88~7.40(m, 6H, 3, 6, Ar'-H), 8.53(d, 1H, J=8 Hz, 5-H), 8.98(s, 1H, CH=N), 9.39(s, 1H, OH)	325(100%, M ⁺), 310, 296, 282, 266, 218, 120
3l	0.84(t, 3H, J=7 Hz, Hex-CH ₃), 1.30~1.64(m, 8H, Hex-4CH ₂), 2.58(t, 2H, 6-CH ₂ -), 3.96(s, 3H, 7-OCH ₃), 6.64(s, 1H, 3-H), 6.76(s, 1H, 8-H), 6.83(d, 2H, J=8 Hz, 3', 5'-H), 7.35(d, 2H, J=8 Hz, 2', 6'-H), 8.55(s, 1H, 5-H), 8.81(s, 1H, CH=N), 9.72(s, 1H, OH)	379(100%, M ⁺), 362, 351, 308, 294, 280, 252, 120
3m	0.84(t, 3H, J=7 Hz, Hex-CH ₃), 1.20~1.65(m, 8H, Hex-4CH ₂), 2.57(t, 2H, 6-CH ₂ -), 3.89(s, 3H, 7-OCH ₃), 6.88~7.41(m, 6H, 3, 8, Ar'-H), 8.54(d, 1H, J=8 Hz, 5-H), 9.01(s, 1H, CH=N)	379(100%, M ⁺), 362, 351, 308, 294, 280, 265, 120
3n	2.19(s, 3H, 8-CH ₃), 3.90(s, 3H, 7-OCH ₃), 6.66(s, 1H, 3-H), 6.81(d, 2H, J=8 Hz, 3', 5'-H), 7.01(d, 1H, J=8 Hz, 6-H), 7.35(d, 2H, J=8 Hz, 2', 6'-H), 8.63(d, 1H, J=8 Hz, 5-H), 8.81(s, 1H, CH=N), 9.68(s, 1H, OH)	309(100%, M ⁺), 294, 292, 281, 266, 238, 204, 162, 120
3o	2.21(s, 3H, 8-CH ₃), 3.92(s, 3H, 7-OCH ₃), 6.86~7.40(m, 6H, 3, 6, Ar'-H), 8.60(d, 1H, J=8 Hz, 5-H), 8.98(s, 1H, CH=N), 9.38(s, 1H, OH)	309(100%, M ⁺), 294, 292, 281, 280, 266, 252, 238, 120
3p	2.31(s, 3H, 7-OCOCH ₃), 6.74(s, 1H, 3-H), 6.80(d, 2H, J=8 Hz, 3', 5'-H), 7.14(d, 1H, J=2 Hz, 8-H), 7.27(dd, 1H, J=2/8 Hz, 6-H), 7.00(d, 2H, J=8 Hz, 2', 6'-H), 8.89(d, 1H, J=8 Hz, 5-H), 8.96(s, 1H, CH=N)	323(M ⁺), 281, 280, 264, 253, 252, 134, 120, 43(100%)
3q	2.31(s, 3H, 7-OCOCH ₃), 6.87~7.47(m, 7H, 3, 6, 8, Ar'-H), 8.87(d, 1H, J=8 Hz, 5-H), 9.00(s, 1H, CH=N), 9.42(s, 1H, OH)	323(M ⁺), 295, 281, 264, 252, 120(100%)

该类化合物的体外抑癌活性与苯乙烯基香豆素^[2,3]相近。由于氨基苯甲酸的西佛碱大多不稳定,所以制备了一些含羟基的衍生物。构效关系研究表明:有活性的化合物都是 4-位西佛碱,而 6-或 7-位西

佛碱无效;这与苯乙烯基香豆素 6-或 7-位衍生物活性较 4-位衍生物活性较高的结果相反,可能是由于 4-位衍生物与 6-或 7-位衍生物在空间形象上的差别造成的。有活性的 4-位西佛碱 4'-位为羟基时(3e)

抑癌活性稍强于 4'-羧基(3h)化合物,4'-位为甲氧基或 2'-位为羟基的衍生物也有活性,说明氨基化合物的苯环上给电子基团对活性影响较好。香豆素苯环 6-位引入脂溶性大的正己基(3m)对活性影响不大。

Table 3 *In vitro* antitumor activities of the analogues MTT IC₅₀ (μg·mL⁻¹)

No.	HL-60	KB	HCT-8	Bel-7402
3e	>10	6.7	3.3	6.2
3d	>10	6.3	5.9	5.9
3e	>10	5.2	6.1	6.3
3f	>10	6.6	6.2	5.7
3g	>10	6.2	7.0	7.0
3h	>10	8.6	7.7	7.8
3j	>10	>10	9.8	9.5
3k	>10	7.9	6.4	6.1
3m	>10	7.6	6.2	5.5
3o	>10	6.3	6.2	6.2
3p	>10	5.2	6.1	6.3
3q	>10	5.8	6.1	5.9

实 验 部 分

熔点用 Yanaco MP-500D 型熔点仪测定,温度未校正。Jeol-90 型核磁共振仪,TMS 为内标。质谱仪为 VG ZAB-2F 型。元素分析仪为 Carlo-Erba 1106 型。薄层色谱硅胶 GF₂₅₄ 柱色谱硅胶 H 为青岛海洋化工厂产品。所用试剂、溶剂均为市售。不同取代的 4-甲基香豆素^[3]以及 6-甲酰基香豆素^[5],4-甲基-7-甲酰基香豆素^[6]和不同取代的 4-甲酰基香豆素^[4]按文献方法制备。

6-(4'-羟基苯基)亚胺次甲基香豆素(化合物 1a)的合成(通法):6-甲酰基香豆素 300 mg(1.7 mmol),对羟基苯胺 200 mg(1.8 mmol)溶于 95%乙醇 50 mL,滴入冰醋酸 1 滴,回流 1 h,冷却析出黄色晶体 340 mg,收率 74.6%。产物用丙酮重结晶,熔点 237℃。化合物 1b,2a,2b,3a~q 均用此法合成。

致谢:核磁共振、质谱、元素分析由本所仪器分析室和化学分析室代测,药理筛选结果由本所筛选室提供。

REFERENCES:

- [1] Ebbinghaus SW, Mohler JL, Marshall ME. Renal cell carcinoma: the background, rationale and current development of coumarin as a potential therapeutic agent [A]. Ó Kennedy. *Coumarin: Biology, Application and Mode of Action* [M]. England: John Wiley and Sons Press, 1997. 209 - 239.
- [2] XU S, XU SP, LI LM. Synthesis of 6- or 7- styrylcoumarin and their anti-tumor activities [J]. *Acta Pharm Sin* (药理学报), 2000, 35(2) :103 - 107.
- [3] XU S, XU SP, LI LM. Synthesis of substituted 4-styrylcoumarin and their anti-tumor activities [J]. *Acta Pharm Sin* (药理学报), 2001, 36(4) :269 - 273.
- [4] Ito K, Maruyama J. Studies on stable diazoalkanes as potential flurogenic reagents I. 7-substituted 4-diazomethylcoumarins [J]. *Chem Pharm Bull*, 1983, 31(9) : 3014 - 3023.
- [5] Jainamma KM, Sethna S. Studies in furan derivatives. Part VII [J]. *J Indian Chem Soc*, 1973, 50(9) : 790 - 792.
- [6] Jainamma KM, Sethna S. Studies in some formylcoumarins [J]. *J Indian Chem Soc*, 1973, 50(9) :606 - 608.

SYNTHESIS OF 4-, 6- OR 7- SUBSTITUTED PHENYLIMINOMETHYLENECOUMARINS AND THEIR ANTICANCER ACTIVITIES

XU Song, XU Shi-ping, LI Lan-min

(Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China)

ABSTRACT: AIM A series of substituted phenyliminomethylenecoumarins derivatives was designed in order to find compounds possessing anticancer activities. **METHODS** Title compounds (1a ~ b, 2a ~ b and 3a ~ q) were synthesized and screened by several anticancer models *in vitro*. **RESULTS** Twenty-one new compounds (1a ~ b, 2a ~ b and 3a ~ q) were synthesized and screened. Structures of the new compounds were determined by MS, HNMR and elemental analysis. Twelve compounds (3c, 3d, 3e, 3f, 3g, 3h, 3j, 3k, 3m, 3o, 3p, 3q) showed inhibitory effects on HCT-8, KB and Bel7402 cell lines *in vitro*. **CONCLUSION** Some compounds had certain anticancer activities and were worth further studying.

KEY WORDS: coumarin; Schiff's base; anticancer activity